How do you approach post-operative SRS for melanoma metastases in the setting of immunotherapy?  

Do you uniformly recommend adjuvant treatment or reserve SRS for a subtotal resection and/or recurrent disease?



Answer from: Radiation Oncologist at Academic Institution